Zach Demkovich does product development and project management for new and innovative technologies with RTI International's Women's Global Health Imperative (WGHI) and in collaboration with our Global Health Technologies (GHT) and Technology Advancement & Commercialization (TAC) groups. He has several years of experience managing preclinical stages and GMP manufacturing of an implantable drug delivery system for HIV prevention. More recently, he’s been gaining experience in the IND submission process for all sorts of investigational products like vaccines, devices, biologics, and cell & gene therapies.
Mr. Demkovich’s notable publications include Predicting pharmacokinetics of a tenofovir alafenamide subcutaneous implant using physiologically based pharmacokinetic modelling and Characterization of a reservoir-style implant for sustained release of tenofovir alafenamide (TAF) for HIV pre-exposure prophylaxis (PrEP).
